Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca and Blueprint Medicine Corporation.

Advances In™ NSCLC: How Do Brain Metastases Impact Treatment Decision-Making Along Lines of Care?

Release Date: December 15, 2020
Expiration Date: December 15, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of patients with NSCLC who develop brain metastases, with a forward-looking perspective on how new and novel agents might impact clinical practice. Current and emerging therapies, along with a discussion of key clinical trial data and will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Blueprint Medicine Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and pulmonologists who treat patients with NSCLC. Nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment and management of NSCLC will also be invited to participate in the activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss unmet needs regarding brain metastases for patients with advanced NSCLC
• Review the mechanistic rationale for emerging therapies as it relates to CNS activity
• Evaluate available clinical trial data of therapies with CNS activity and effectiveness along lines of care
• Identify ongoing clinical trials including patients with advanced NSCLC and brain metastases

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Sarah Goldberg, MD, MPH
Sarah Goldberg, MD, MPH
Associate Professor
Department of Medicine, Division of Medical Oncology
Yale School of Medicine
New Haven, CT

Disclosures: Grant/Research Support: AstraZeneca, Boehringer Ingelheim; Consultant: AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Sanofi Genzyme, Regeneron

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By